Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598440 · ClinicalTrials.gov registry record · Phase 4
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 341
- Enrollment target
NCT02598440 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 341 participants.
The verdict
NCT02598440, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 341 participants
- Enrollment target
Study Summary
This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.
Interventions
- DRUG Alendronate
- DRUG Ibandronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02598440
The ClinicalTrials.gov registry entry for NCT02598440 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alendronate is the first listed.
NCT02598440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02598440 about?
NCT02598440 is a clinical study titled "A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis". This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.
What is the current status of trial NCT02598440?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 341 participants. The study started on 2004-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT02598440?
The interventions under investigation include: Alendronate (DRUG), Ibandronate (DRUG).
Who is sponsoring clinical trial NCT02598440?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.